Updates in Treatment Approaches for Prostate Cancer
EP. 1: Overview of Metastatic HSPC: Diagnosis and Risk Stratification
ByRana R. McKay, MD, University of California San Diego Medical Center,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD,Arash Rezazadeh Kalebasty, MD Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.
EP. 2: Systemic Treatment Armamentarium in Metastatic HSPC
ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.
EP. 3: What is the Role of Locoregional Therapy in Metastatic HSPC?
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.
EP. 4: Informing Systemic Therapy Selection With Negative Data in HSPC
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.
EP. 5: Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.
EP. 6: Advent of PARP Inhibitors in Metastatic CRPC
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.
EP. 7: Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.
EP. 8: Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.
EP. 9: Radioligands in the Treatment of Metastatic CRPC: Radium-223
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.
EP. 10: Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
EP. 11: Novel Therapeutic Targets in Metastatic CRPC
ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.
EP. 12: Potential for CDK4/6 Inhibitors in Metastatic CRPC
ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.
EP. 13: Ongoing Clinical Trials in the Metastatic CRPC Setting
ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.
EP. 14: CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care
ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
